Mergers & Acquisitions - Generics, Patents

Filter

Current filters:

GenericsPatents

Popular Filters

Generics briefs: Actavis/Warner Chilcott M&A delay; Canasa patent challenge

11-07-2013

US generics major Actavis (NYSE: ACT) and Ireland-based Warner Chilcott (Nasdaq: WCRX) have each received…

ActavisAptalis PharmaCanasaGenericsLegalMergers & AcquisitionsMylan LaboratoriesNorth AmericaPatentsWarner Chilcott

Actavis in OxyContin patent settlement; Valeant takeover bid "on hold"?

29-04-2013

US generic major Actavis (NYSE: ACT) has entered into an agreement with privately-held Purdue Pharma…

ActavisGenericsMergers & AcquisitionsNeurologicalNorth AmericaOxyContinPatentsPurdue PharmaValeant Pharmaceuticals

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

12-02-2013

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Actavis reportedly to be acquired by Watson; debuts generic Zomig

22-03-2012

Icelandic generic drugmaker Actavis is said to be in talks to be acquired by US peer Watson Pharmaceuticals…

ActavisAstraZenecaEuropeGenericsMarkets & MarketingMergers & AcquisitionsNeurologicalPatentsWatson PharmaceuticalsZolmitriptanZomig

Company Spotlight

ImmunoGen

ImmunoGen

Back to top